-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

674 Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Clinical Research, Diseases, Study Population, Human
Sunday, December 8, 2024: 4:45 PM

Pieter Sonneveld, MD1, Meletios A. Dimopoulos, MD2, Meral Beksac, MD3,4, Bronno van der Holt, PhD1,5*, Francesca Gay, MD, PhD6*, Heinz Ludwig, MD7, Sonja Zweegman, MD, PhD8, Vladimir Maisnar, MD, PhD9*, Maria Teresa Petrucci, MD10*, Paolo Corradini, MD11, Francesca Patriarca, MD, PhD12*, Angelo Belotti, MD13*, Micol Quaresima, MD14*, Mariella Grasso, MD15*, Massimo Offidani, MD16*, Laura Paris, MD17*, Anna Marina Liberati, MD18, Markus Hansson, MD, PhD19*, Heleen Visser-Wisselaar, PhD5*, Giulia Fumero, MSc20*, Renato Zambello, MD21*, Paula F Ypma, MD, PhD22*, Anna Pascarella, MD23*, Niels Frost Andersen, MD, PhD24*, Alexandra Croockewit, MD, PhD25*, Mario Boccadoro, MD20 and Michele Cavo, MD26,27*

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
3Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
4Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey
5HOVON Foundation, Rotterdam, Netherlands
6Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
7Wilhelminen Cancer Research Institute, c/o Department of Medicine I, Clinic Ottakring, Vienna, Austria
8Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
94th Department of Medicine - Haematology, Charles University Hospital and Faculty of Medicine Hradec Kralove, Hradec Kralove, Czech Republic
10Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
11Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Università di Milano, Milano, Italy
12Hematologic Clinic and Transplant Center, University Hospital of Central Friuli, DMED, University of Udine, Udine, Italy
13Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
14Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
15Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
16AOU delle Marche, Ancona, Italy
17Division of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
18A.O. Santa Maria di Terni – Università degli Studi di Perugia, Terni–Perugia, Italy
19Department of Hematology, Skåne University Hospital, Lund, Sweden
20European Myeloma Network, EMN, Italy
21Department of Medicine (DIMED), Hematology and Clinical Immunology, Padua University, Padua, Italy
22Department of Hematology, HagaZiekenhuis, Den Haag, Netherlands
23UOC Ematologia, Ospedale dell'angelo, Venezia Mestre, Italy
24Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
25Department of Hematology, Radboud University Medical Centre, Nijmegen, Netherlands
26IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
27Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

AIM. To evaluate the long-term overall survival (OS) associated with bortezomib-lenalidomide-dexamethasone (VRD) consolidation treatment in transplant-eligible patients with newly diagnosed multiple myeloma (NDTE-MM).

METHODS. The EMN02/HOVON95 trial compared consolidation treatment with 2 cycles of VRD or no consolidation followed by continuous lenalidomide maintenance until progression or intolerance. The primary study endpoint was progression-free survival (PFS). Here we report the secondary endpoint OS. This trial is registered with the EU Clinical Trials Register (EudraCT 2009-017903-28) and ClinicalTrials.gov (NCT01208766).

RESULTS. In the EMN02/HOVON95 trial, 1503 NDTE-MM patients were enrolled, 1500 of whom were eligible. Patients received induction treatment with bortezomib-cyclophosphamide-dexamethasone (VCD) followed by the first randomisation (R1) for intensification with single or double high-dose melphalan plus autologous stem-cell transplantation (HDM1/2-ASCT) or bortezomib-melphalan-prednisone (VMP; Cavo et al. Lancet Haematology 2020; 7(6): e456-e468). Subsequently, eligible patients were randomized (R2) to receive VRD consolidation (n=451) or no consolidation (n=427). As reported before, the rates of complete response or better (≥CR) after consolidation vs no consolidation before the start of lenalidomide maintenance were 34% vs 18%, respectively (p<0.001). The median duration of maintenance was 33 months in the no consolidation vs 36 months in the consolidation arm. Response ≥CR on protocol including maintenance was 59% with consolidation vs 48% without (p=0.001). After a median follow-up of 110 months after R2, 545 patients were still alive: 239 in the no consolidation vs 306 in the consolidation arm. 10-year OS after R2 was 50% (95% CI 44–55%) in the no consolidation vs 64% (95% CI 58–68%) in the consolidation arm. As the Kaplan–Meier curves were crossing after about 3.5 years, and the proportional hazards assumption was violated, the restricted mean survival time (RMST) method was used to compare OS between the consolidation vs no consolidation arms. The RMST at 9 years was 4.7 months longer in the consolidation vs no consolidation arm (95% CI 0.3–9.1; p=0.035). The OS benefit was observed in all treatment groups stratified according to R1: i.e., HDM1 (10-year OS, 54% vs 61%), HDM1+2 (58% vs 74%), and VMP (39% vs 62%). Favorable OS in the consolidation arm was observed in most of the predefined subgroups, according to International Staging System (ISS) stage, cytogenetic risk, and Revised (R-)ISS stage, although not in patients with high-risk cytogenetic abnormalities (HRCA) and especially not in patients with del(17p13). ISS stage 3, HRCA, and R-ISS stage 3 were significantly associated with adverse OS in univariable analyses. Toxicity from VRD was acceptable and manageable. The cumulative incidence of second primary malignancies (excluding skin cancer) at 10 years after R2 was 10% vs 12% in the consolidation vs no consolidation arms.

CONCLUSIONS. To the best of our knowledge, this is the first randomized trial that demonstrated a survival advantage of consolidation treatment in transplant-eligible patients with newly diagnosed multiple myeloma.

SUPPORT. This independent trial was supported by the Dutch Cancer Society (grant 2010-4798), the HOVON Dutch trial group, the European Myeloma Network, and by unrestricted grants from Celgene (Bristol Myers Squibb) and Janssen (Johnson & Johnson).

Disclosures: Sonneveld: Oncopeptides: Patents & Royalties; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; European Myeloma Network: Other: President; Pfizer: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding. Dimopoulos: Swixx: Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Menarini: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Beksac: Amgen: Speakers Bureau; GSK: Research Funding; Menarini: Consultancy, Other: advisory; Takeda: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Speakers Bureau; Sanofi: Speakers Bureau; Janssen: Research Funding, Speakers Bureau. van der Holt: Intergroupe Francophone du Myelome (IFM): Other: Honoraria for data safety monitoring board membership. Gay: GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees. Ludwig: Bristol Myers Squibb: Other: Honoraria (speakers bureau, advisory boards, DMC); Pfizer: Other: Honoraria (speakers bureau, advisory boards, DMC); Janssen: Other: Honoraria (speakers bureau, advisory boards, DMC); GlaxoSmithKline: Other: Honoraria (speakers bureau, advisory boards, DMC); Takeda: Other: Honoraria (speakers bureau, advisory boards, DMC); Amgen: Research Funding; Sanofi: Other: Honoraria (speakers bureau, advisory boards, DMC), Research Funding; Menarini: Other: Honoraria (speakers bureau, advisory boards, DMC); Oncopeptides: Other: Honoraria (speakers bureau, advisory boards, DMC). Zweegman: Amgen: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding; Oncopeptides: Membership on an entity's Board of Directors or advisory committees. Petrucci: Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSF: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Jansen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees; Menarini: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Corradini: Daiichi Sankyo: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); Roche: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations; Gilead/Kite: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations; GlaxoSmithKline: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); Takeda: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations; SOBI: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); Bristol Myers Squibb: Other: Support for travel and accommodations; Sanofi: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); Incyte: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); Janssen: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations; Kyowa Kirin: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); Pfizer: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); Novartis: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations; Celgene: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations; Amgen: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations; AbbVie: Other: Honoraria (for consultancy, participation in advisory boards, or lectures); support for travel and accommodations. Patriarca: Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; Menarini: Honoraria. Belotti: Janssen: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Menarini Stemline: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Quaresima: Novartis: Membership on an entity's Board of Directors or advisory committees. Offidani: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Paris: Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodation; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Menarini Stemline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodation; Takeda: Honoraria, Other: Travel, accommodation; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodation. Liberati: Servier: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria; IQVIA: Honoraria, Other: Support for travel; PSI: Research Funding; Bristol Myers Squibb: Honoraria, Other: Support for travel, Research Funding; BeiGene: Research Funding; LoxoOncology: Research Funding; Dr. Reddy's Lab.: Research Funding; Fibrogen: Research Funding; Archigen: Research Funding; Onconova: Research Funding; Karyopharm: Research Funding; Oncopeptides: Research Funding; GlaxoSmithKline: Research Funding; Morphosys: Research Funding; Novartis: Other: Support for travel, Research Funding; Verastem: Other: Support for travel, Research Funding; Sanofi: Other: Support for travel, Research Funding; Janssen: Honoraria, Other: Support for travel, Research Funding; Millennium: Research Funding; AbbVie: Honoraria, Other: Support for travel, Research Funding; Celgene: Honoraria, Other: Support for travel, Research Funding; Roche: Other: Support for travel, Research Funding; Takeda: Other: Support for travel, Research Funding. Zambello: Janssen: Membership on an entity's Board of Directors or advisory committees; GlaxoSMithKline: Membership on an entity's Board of Directors or advisory committees; Menarini Stemline: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees. Ypma: Novartis: Other: Remuneration as a speaker for conference without personal financial compensation; Johnson & Johnson: Other: Partial reimbursement of conference attendance costs; remuneration as a speaker for conference without personal financial compensation. Boccadoro: Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; AbbVie: Honoraria; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Mundipharma: Research Funding; Sanofi: Honoraria, Research Funding.

OffLabel Disclosure: This presentation includes discussion of the off-label use of a drug or drugs for the treatment of multiple myeloma (bortezomib, lenalidomide, dexamethasone, cyclophosphamide, melphalan, and prednisone).

*signifies non-member of ASH